Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Has NICE Or Other Agencies Endorsed Cannabis for Depression or Bipolar in Mood Disorders? 

Posted
Updated
ByMy Patient Advice
Author: Dr. Clarissa Morton, PharmD

The current position on NICE cannabis guidance makes it clear that cannabis-based medicines are not routinely recommended for depression or bipolar disorder. NICE, the UK’s health authority, has issued advice primarily for severe epilepsy, multiple sclerosis, and chemotherapy-induced nausea, but not for mood disorders. This means patients with a mental health condition like depression or bipolar face limited access through the NHS. 

Other agencies have also taken a cautious approach. Concerns over inconsistent evidence and potential side effects prevent broader approval. For now, the NICE cannabis policy reflects a need for more robust clinical trials before cannabis can be endorsed for psychiatric use. 

Can I use Medical Cannabis for Pain Relief?

Regulatory Stance on Cannabis for Mental Health 

Understanding NICE cannabis guidance means examining how agencies set rules around prescribing. 

NICE Cannabis Policy 

The current NICE cannabis policy advises against routine prescribing for depression and bipolar disorder, citing insufficient evidence on effectiveness and safety. 

Regulatory Guidance on Cannabis 

Across Europe and the UK, regulatory guidance on cannabis is consistent: cannabis-based medicines remain experimental for psychiatric care, and prescriptions are typically limited to physical conditions. 

Agency Endorsement of Cannabis 

There has been no full agency endorsement of cannabis for mental health treatment. Some private clinics may offer cannabis off-label, but this is outside mainstream NHS care. 

In summary, NICE cannabis guidance does not endorse cannabis for depression or bipolar, leaving patients reliant on private pathways. Stronger research evidence will be required before any shift in official recommendations. 

For individuals considering medical cannabis for mood management, providers like LeafEase can offer supportive consultations tailored to safe and personalised care. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Mood Disorders. 

Dr. Clarissa Morton, PharmD
Author

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Categories